Patents Assigned to Inventiva
-
Publication number: 20260327219Abstract: The present disclosure relates to a process for manufacturing lanifibranor which comprises reacting N-(4-chloro-2-iodo-phenyl)-1,3-benzothiazole-6-sulfonamide with 5-hexynoic acid in the presence of a Palladium catalyst and a copper salt.Type: ApplicationFiled: June 25, 2026Publication date: October 22, 2026Applicant: INVENTIVAInventors: Frederic BELL, Cécile BROSSEAU, Viktoriia ZUBAR
-
Publication number: 20260256748Abstract: The present invention relates to the use of lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof for the treatment of splanchnic vasodilatation in a patient with a liver condition.Type: ApplicationFiled: June 4, 2024Publication date: September 3, 2026Applicant: INVENTIVAInventors: Guillaume WETTSTEIN, Jean-Louis JUNIEN, Sander LEFERE, Anneleen HELDENS, Anja GEERTS
-
Patent number: 12686678Abstract: Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.Type: GrantFiled: November 24, 2023Date of Patent: July 21, 2026Assignee: INVENTIVAInventors: Minhua Chen, Hongyan Zhu
-
Publication number: 20260193246Abstract: The present disclosure relates to a process for manufacturing lanifibranor which comprises reacting N-(4-chloro-2-iodo-phenyl)-1,3-benzothiazole-6-sulfonamide with 5-hexynoic acid in the presence of a Palladium catalyst and a copper salt.Type: ApplicationFiled: March 4, 2026Publication date: July 9, 2026Applicant: INVENTIVAInventors: Frederic BELL, Cécile BROSSEAU, Viktoriia ZUBAR
-
Publication number: 20250290937Abstract: The present disclosure relates to methods for identifying a subject as eligible for treatment with lanifibranor, methods for treating a subject suffering from liver disease comprising administering lanifibranor to said subject and monitoring a subject's risk of experiencing a side effect caused by lanifibranor treatment.Type: ApplicationFiled: March 14, 2025Publication date: September 18, 2025Applicant: INVENTIVAInventors: Louis H. GRIFFEL, Martine BAUDIN
-
Patent number: 12291526Abstract: The present invention relates to deuterated derivatives of lanifibranor, in particular for use in therapy, specifically in the treatment of fibrotic diseases.Type: GrantFiled: July 26, 2019Date of Patent: May 6, 2025Assignee: INVENTIVAInventors: Christian Montalbetti, Benaissa Boubia
-
Publication number: 20240408069Abstract: The present disclosure relates to a method for assessing the effectiveness of a treatment with lanifibranor in a patient with a liver disease, the method comprising: a) in vitro measuring levels of a combination of biomarkers consisting of adiponectin, ferritin, MMP9 and transferrin in a biological sample from the patient; and b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).Type: ApplicationFiled: June 6, 2024Publication date: December 12, 2024Applicant: INVENTIVAInventors: Pierre BROQUA, Philippe HUOT-MARCHAND, Lucile DZEN, Jérôme BOURSIER, Marine ROUX, Hugo HERVÉ
-
Publication number: 20240410904Abstract: The present disclosure relates to a method of assessing the effectiveness of a treatment with lanifibranor in a patient with a liver disease, the method comprising: a) in vitro measuring levels of a combination of biomarkers consisting of CK18M65, hyaluronic acid, fructosamine and ALT in a biological sample from the patient; b) assessing the effectiveness of the treatment with lanifibranor as a function of the levels measured in step a).Type: ApplicationFiled: June 6, 2024Publication date: December 12, 2024Applicant: INVENTIVAInventors: Pierre BROQUA, Philippe HUOT-MARCHAND, Lucile DZEN, Jérôme BOURSIER, Marine ROUX, Hugo HERVÉ
-
Patent number: 11999758Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and are as defined in the description.Type: GrantFiled: October 2, 2019Date of Patent: June 4, 2024Assignee: INVENTIVAInventors: Martine Barth, Sylvie Contal, Jean-Louis Junien, Christine Massardier, Christian Montalbetti, Anne Soude
-
Patent number: 11504380Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.Type: GrantFiled: November 8, 2019Date of Patent: November 22, 2022Assignee: INVENTIVAInventors: Guillaume Wettstein, Pierre Broqua, Jean-Louis Junien
-
Patent number: 10414739Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The compounds of formula (I) are inhibitors of the YAP/TAZ-TEAD interaction.Type: GrantFiled: October 14, 2016Date of Patent: September 17, 2019Assignee: INVENTIVAInventors: Martine Barth, Sylvie Contal, Christian Montalbetti, Luc Spitzer
-
Patent number: 10383858Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.Type: GrantFiled: July 24, 2018Date of Patent: August 20, 2019Assignee: INVENTIVAInventors: Irena Konstantinova, Jean-Michel Luccarini, Jean-Louis Junien, Pierre Broqua
-
Patent number: 10092540Abstract: The present invention relates to the use of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside in the treatment of a mucopolysaccharidosis such as type I mucopolysaccharidosis.Type: GrantFiled: January 31, 2017Date of Patent: October 9, 2018Assignee: INVENTIVAInventors: Philippe Masson, Jean-Louis Junien, Mireille Tallandier
-
Patent number: 10052311Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.Type: GrantFiled: June 12, 2015Date of Patent: August 21, 2018Assignee: INVENTIVAInventors: Irena Konstantinova, Jean-Michel Luccarini, Jean-Louis Junien, Pierre Broqua
-
Patent number: 9561246Abstract: The present invention relates to a method of treatment of a mucopolysaccharidosis with 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-?-D-xylopyranoside.Type: GrantFiled: October 3, 2014Date of Patent: February 7, 2017Assignee: InventivaInventors: Philippe Masson, Jean-Louis Junien
